99465-09-5

Basic information

• Product Name: 5-BROMO-1H-QUINOLIN-2-ONE
• Synonyms: 5-BROMO-1H-QUINOLIN-2-ONE;5-BROMOQUINOLIN-2(1H)-ONE;5-Bromoquinolin-2(1H)-on
• CAS NO: 99465-09-5
• Molecular Formula: C₉H₆BrNO
• Molecular Weight: 224.056
• Mol File: 99465-09-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-BROMO-1H-QUINOLIN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-1H-QUINOLIN-2-ONE(99465-09-5)
• EPA Substance Registry System: 5-BROMO-1H-QUINOLIN-2-ONE(99465-09-5)

Safety Data

• Hazardous Substances Data: 99465-09-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-BROMO-1H-QUINOLIN-2-ONE is used as a building block for the synthesis of various biologically active compounds due to its unique chemical structure and potential to contribute to the development of new drugs.
Used in Agrochemical Industry:
5-BROMO-1H-QUINOLIN-2-ONE is used as a precursor in the creation of agrochemicals, leveraging its antimicrobial and antifungal properties to enhance crop protection and management.
Used in Antimicrobial and Antifungal Applications:
5-BROMO-1H-QUINOLIN-2-ONE is used as an antimicrobial and antifungal agent, exhibiting properties that make it a potential candidate for the development of new drugs to combat resistant strains of bacteria and fungi.
Used in Biochemical and Analytical Studies:
5-BROMO-1H-QUINOLIN-2-ONE is used as a fluorescent probe in biochemical and analytical research, taking advantage of its fluorescent properties to aid in the study of biological processes and the development of diagnostic tools.

Upstream product

• 4964-71-0 5-bromoquinoline 
• 917341-34-5 (2E)-N-(3-bromophenyl)-3-phenylprop-2-enamide 
• 349426-35-3 N-(3-bromophenyl)cinnamamide 
• 99465-18-6 (E)-N-(3-bromophenyl)-3-ethoxypropenamide 

Downstream Products

• 120258-64-2 2,5-dibromo-quinoline 
• 99455-13-7 5-bromo-2-chloroquinoline 
• 99455-15-9 7-bromo-2-chloro-quinoline 
• 1404431-45-3 5-bromo-1-(4-methoxybenzyl)quinolin-2(1H)-one 
• 1219130-53-6 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolone 
• 1404431-46-4 7-bromo-3-(4-methoxybenzyl)-3,7b-dihydro-1H-cyclopropa[c]quinolin-2(1aH)-one 
• 99455-06-8 5-bromo-2-methoxyquinoline 
• 347146-12-7 5-bromoquinolin-2-amine 

Relevant articles and documents

NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS

Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R3, R4, R4a, R5a, R5b, R5c, R5d, R5e, R6a, R6b, and R6c are defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT

Novel heterocyclic biaryl derivatives were disclosed which are useful as pharmaceutical agents and which exhibit a phosphodiesterase-inhibitory action. The heterocyclic biaryl derivatives are represented by the following general formula (1): wherein the H

2-QUINOLINONE AND 2-QUINOXALINONE- DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS

The present invention relates to compounds of Formula (I) : and pharmaceutically acceptable salts thereof, to their use in the treatment of bacterial infections, and to their methods of preparation.

COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS

The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

2(1H)-Quinolinones with cardiac stimulant activity. 1. Synthesis and biological activities of (six-membered heteroaryl)-substituted derivatives

A series of (six-membered heteroaryl)-substituted 2(1H)-quinolinones was synthesized, and structure-activity relationships for cardiac stimulant activity were determined. Most compounds were prepared by acidic hydrolyisis of a heteroaryl-2-methoxyquinoline obtained by palladium-catalyzed cross-coupling methodology. Direct reaction of a pyridinylzinc reagent with a 6-haloquinolinone also proved successful. In anesthetized dogs, 6-pyridin-3-yl-2(1H)-quinolinone (3; 50 μg/kg) displayed greater inotropic activity (percentage increase in dP/dt max) than positional isomers, and potency was maintained with either mono- or di- alkylpyridinyl substituents. Introduction of a 4- or 7- methyl group into 3 reduced inotropic activity, whereas the 8-isomer proved to be the most potent member of the series. Compound 26 and the 2,6-dimethylpyridinyl analogue (27 were approximately 6 and 3 times more potent than milrinone. Several quinolinones displayed positive inotropic activity (decrease in QA interval) in conscious dogs after oral administration (1 mg/kg), and 26, 27 were again the most potent members of the series. Compound 27 (0.25, 0.5, 1.0 mg/kg po) demonstrated dose-related cardiac stimulant activity, which was maintained for at least 4 h. No changes in heart rate were observed. Compounds 3, 4, 26, and 27 also selectively stimulated the force of contraction, rather than heart rate, in the dog heart-lung preparation. For a 50% increase in dP/dt max with 27, heart rate changed by less than 10 beats/min. In norepinephrine contracted rabbit femoral artery and saphenous vein, 27 produced dose related (5 x 10-7 to 5 x 10-4 M) vasorelaxant activity. The combined cardiac stimulant and vasodilator properties displayed by 27, coupled with a lack of effect on heart rate, should be beneficial for the treatment of congestive heart failure.